Biotechnology - Sarepta Therapeutics

Filter

Current filters:

Sarepta Therapeutics

Popular Filters

US FDA clears pathway for Sarepta’s eteplirsen filing by year end

22-04-2014

US RNA-based drug developer Sarepta Therapeutics it plans to submit a New Drug Application to the US…

BiotechnologyeteplirsenNorth AmericaRare diseasesRegulationSarepta TherapeuticsUSA

Sarepta plunges as FDA questions eteplirsen trial results

Sarepta plunges as FDA questions eteplirsen trial results

12-11-2013

Shares of US RNA-based drug developer Sarepta Therapeutics plummeted in pre-market trading on November…

BiotechnologydrisaperseneteplirsenGlaxoSmithKlineNorth AmericaRare diseasesRegulationResearchSarepta Therapeutics

Sarepta to file NDA for its Duchenne muscular dystrophy compound

25-07-2013

US RNA-based drug developer Sarepta Therapeutics (Nasdaq: SRPT) plans to submit a New Drug Application…

BiotechnologyeteplirsenNorth AmericaRare diseasesRegulationSarepta Therapeutics

Sarepta rockets as eteplirsen seen to significantly benefit Duchenne patients

04-10-2012

US RNA-based drug developer Sarepta Therapeutics (Nasdaq: SRPT) saw its shares rocket 200% to $44.93…

BiotechnologyeteplirsenPharmaceuticalRare diseasesResearchSarepta Therapeutics

Sarepta's shares rocket on positive results with eteplirsen in Duchenne muscular dystrophy

25-07-2012

US RNA-based drug developer Sarepta Therapeutics (Nasdaq: SRPT) saw its shares leap 140% to $8.30 yesterday…

AVI BioPharmaBiotechnologyeteplirsenRare diseasesResearchSarepta Therapeutics

Back to top